IL6 and Castleman disease: The use of mAbs, such as adalimumab, primarily used for inflammatory bowel disease and certain autoimmune diseases, and siltuximab, an interleukin-6 (IL-6) inhibitor employed in the treatment of Castleman’s disease, illustrates the principle of modulating inflammatory pathways exacerbated by SnCs [42,44].